系统性红斑狼疮大型多中心队列中严重感染的发生率、相关因素及临床影响
基于西班牙风湿病学会狼疮登记(RELESSER)3658例SLE患者的回顾性队列,19.3%患者发生至少1次严重感染,发生率为29.2/1000患者年。多因素Cox回归显示诊断时年龄、拉丁美洲族裔、糖皮质激素≥10mg/日、免疫抑制剂、因SLE住院、Katz严重度指数、SLICC/ACR损伤指数及吸烟与感染相关,抗疟药使用时长具保护作用。
要点
- SLE患者严重感染发生率为29.2/1000患者年,19.3%患者至少发生1次。
- 糖皮质激素≥10mg/日及免疫抑制剂使用与严重感染风险增加相关。
- 抗疟药使用时长延长与严重感染风险降低相关。
核心结论
- 严重感染是SLE患者不良预后的预测因素,在拉丁美洲人群中更常见,并与年龄、既往感染及吸烟相关。
- 抗疟药的使用发挥了保护作用。
研究设计与样本
- 回顾性多中心队列研究,纳入西班牙风湿病学会狼疮登记(RELESSER)中符合≥4项ACR-97 SLE标准的3658例患者。
- 比较有无感染患者的SLE严重度、损伤、合并症及人口学特征,并构建多变量Cox回归模型计算首次感染的风险比(HR)。
主要发现
- 共705例(19.3%)患者发生至少1次严重感染,累计记录1227次严重感染,发生率为29.2(95%CI:27.6-30.9)/1000患者年。
- 从首次感染到第二次感染的时间显著短于从诊断到首次感染的时间(p<0.000)。
- 呼吸道感染最常见(35.5%),但血流感染是感染所致死亡的最常见原因(42.0%)。
关键数值与推荐
- 诊断时年龄与感染相关(HR=1.016,95%CI:1.009-1.023)。
- 拉丁美洲(美洲印第安-混血)族裔与感染相关(HR=2.151,95%CI:1.539-3.005)。
- 糖皮质激素≥10mg/日与感染相关(HR=1.271,95%CI:1.034-1.561);免疫抑制剂与感染相关(HR=1.348,95%CI:1.079-1.684)。
- 因SLE住院与感染相关(HR=2.567,95%CI:1.905-3.459);Katz严重度指数与感染相关(HR=1.160,95%CI:1.105-1.217)。
- SLICC/ACR损伤指数与感染相关(HR=1.069,95%CI:1.031-1.108);吸烟与感染相关(HR=1.332,95%CI:1.121-1.583);抗疟药使用时长(月)具保护作用(HR=0.998,95%CI:0.997-0.999)。
临床怎么用
- 对SLE患者应评估严重感染风险,尤其关注高龄诊断、拉丁美洲族裔、吸烟及既往感染史者。
- 控制糖皮质激素剂量(≥10mg/日增加风险)及免疫抑制剂使用,并鼓励戒烟以降低感染风险。
- 抗疟药使用时长与感染风险降低相关,支持在无禁忌时持续使用抗疟药。
局限性
- 本研究为回顾性队列研究,可能存在信息偏倚与混杂因素。
- 研究基于西班牙风湿病学会狼疮登记(RELESSER)队列,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To estimate the incidence of severe infection and investigate the associated factors and clinical impact in a large systemic lupus erythematosus (SLE) retrospective cohort. METHODS: All patients in the Spanish Rheumatology Society Lupus Registry (RELESSER) who meet ≥4 ACR-97 SLE criteria were retrospectively investigated for severe infections. Patients with and without infections were compared in terms of SLE severity, damage, comorbidities, and demographic characteristics. A multivariable Cox regression model was built to calculate hazard ratios (HRs) for the first infection. RESULTS: A total of 3658 SLE patients were included: 90% female, median age 32.9 years (DQ 9.7), and mean follow-up (months) 120.2 (±87.6). A total of 705 (19.3%) patients suffered ≥1 severe infection. Total severe infections recorded in these patients numbered 1227. The incidence rate was 29.2 (95% CI: 27.6-30.9) infections per 1000 patient years. Time from first infection to second infection was significantly shorter than time from diagnosis to first infection (p < 0.000). Although respiratory infections were the most common (35.5%), bloodstream infections were the most frequent cause of mortality by infection (42.0%). In the Cox regression analysis, the following were all associated with infection: age at diagnosis (HR = 1.016, 95% CI: 1.009-1.023), Latin-American (Amerindian-Mestizo) ethnicity (HR = 2.151, 95% CI: 1.539-3.005), corticosteroids (≥10mg/day) (HR = 1.271, 95% CI: 1.034-1.561), immunosuppressors (HR = 1.348, 95% CI: 1.079-1.684), hospitalization by SLE (HR = 2.567, 95% CI: 1.905-3.459), Katz severity index (HR = 1.160, 95% CI: 1.105-1.217), SLICC/ACR damage index (HR = 1.069, 95% CI: 1.031-1.108), and smoking (HR = 1.332, 95% CI: 1.121-1.583). Duration of antimalarial use (months) proved protective (HR = 0.998, 95% CI: 0.997-0.999). CONCLUSIONS: Severe infection constitutes a predictor of poor prognosis in SLE patients, is more common in Latin-Americans and is associated with age, previous infection, and smoking. Antimalarials exerted a protective effect.
引用
- Rúa-Figueroa Í, López-Longo J, Galindo-Izquierdo M, et al. Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus. Semin Arthritis Rheum. 2017. PMID: 28259425. doi:10.1016/j.semarthrit.2017.01.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。